Low molecular weight heparin half life is prolonged in haemodialysed patients.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Ton That.
Explore the source record for details and available documents.
The expression of i-antigen during the in vivo aging of erythrocytes from normal subjects and beta-thalassemic patients was investigated by immunofluorescence labeling and by immunoagglutination. The results showed that the expression of i-antigenic determinants inversely related to the aging of RBCs. This phenomenon could be either the result of a progressive loss of i-antigenic structures or the consequence of i to I transformation occurring during RBCs aging in vivo.
Explore the source record for details and available documents.
We report the use of the orally active converting enzyme inhibitor Captopril in hypertensive patients with mild chronic renal failure. Twenty eight patients were followed for a period of six months. Eleven patients required the addition of furosemide. Mean arterial pressure (MAP) decreased in all but two at six months (MAP: 102 +/- 0.8 vs 133 +/- 2.2mmHg, p less than 0.001). Untoward effects were frequent: the commonest reactions are loss of taste (four patients), skin rashes (11 patients), proteinuria (2 patients), tachycardia (2 cases). These side effects disappeared after reduction of dose (10 cases) or withdrawal (8 cases). Patients on 300mg daily or less were free of any untoward effect. In summary (i) Captopril alone or in combination with furosemide has an antihypertensive effect in patients with chronic renal failure and hypertension; (ii) side effects seem to be dose dependant and a reduced dosage should be used in these patients.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.